PE20100050A1 - Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona - Google Patents
Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinonaInfo
- Publication number
- PE20100050A1 PE20100050A1 PE2009000780A PE2009000780A PE20100050A1 PE 20100050 A1 PE20100050 A1 PE 20100050A1 PE 2009000780 A PE2009000780 A PE 2009000780A PE 2009000780 A PE2009000780 A PE 2009000780A PE 20100050 A1 PE20100050 A1 PE 20100050A1
- Authority
- PE
- Peru
- Prior art keywords
- dosage form
- pharmaceutical dosage
- immediate release
- indolinone derivative
- indolinone
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- -1 TABLET Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Business, Economics & Management (AREA)
- Physics & Mathematics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Pathology (AREA)
- Entrepreneurship & Innovation (AREA)
- Educational Administration (AREA)
- Educational Technology (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA TAL COMO COMPRIMIDO, CAPSULA, SOLUCION ORAL, ELIXIR, EMULSION, MICROGRANULOS, POLVO O GRANULOS, DE UNA SUSTANCIA ACTIVA TAL COMO 3-Z-[1-(4-(N-((4-METIL-PIPERAZIN-1-IL)-METILCARBONIL)-N-METIL-AMINO)-ANILINO)-1-FENIL-METILENO]-6-METOXICARBONIL-2-INDOLINONA-MONOETANOSULFONATO EN UNA CONCENTRACION DE 0,01% A 90% EN PESO DE LA COMPOSICION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157750 | 2008-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100050A1 true PE20100050A1 (es) | 2010-01-29 |
Family
ID=41017080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000780A PE20100050A1 (es) | 2008-06-06 | 2009-06-04 | Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20110190318A1 (es) |
| EP (1) | EP2313087B2 (es) |
| JP (2) | JP5583119B2 (es) |
| KR (1) | KR20110022586A (es) |
| CN (1) | CN102056599A (es) |
| AR (1) | AR072060A1 (es) |
| AU (1) | AU2009254556B2 (es) |
| BR (1) | BRPI0913235A2 (es) |
| CA (1) | CA2726648A1 (es) |
| CL (1) | CL2010001362A1 (es) |
| CO (1) | CO6280468A2 (es) |
| CY (1) | CY1121272T1 (es) |
| DK (1) | DK2313087T4 (es) |
| EA (1) | EA201001857A1 (es) |
| EC (1) | ECSP10010717A (es) |
| ES (1) | ES2711913T5 (es) |
| FI (1) | FI2313087T4 (es) |
| HR (1) | HRP20190181T4 (es) |
| HU (1) | HUE042524T2 (es) |
| IL (1) | IL209055A0 (es) |
| LT (1) | LT2313087T (es) |
| MA (1) | MA32386B1 (es) |
| MX (1) | MX338001B (es) |
| PE (1) | PE20100050A1 (es) |
| PL (1) | PL2313087T5 (es) |
| PT (1) | PT2313087T (es) |
| RS (1) | RS58280B2 (es) |
| SG (1) | SG191607A1 (es) |
| SI (1) | SI2313087T2 (es) |
| TR (1) | TR201901579T4 (es) |
| TW (1) | TW201002692A (es) |
| UA (1) | UA107560C2 (es) |
| UY (1) | UY31876A (es) |
| WO (1) | WO2009147220A1 (es) |
| ZA (1) | ZA201007972B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
| NO2299987T3 (es) * | 2008-06-06 | 2018-07-21 | ||
| JP2015532272A (ja) | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| US9073294B2 (en) | 2013-06-04 | 2015-07-07 | Monosol, Llc | Method for sealing a water-soluble film by applying a sealing solution |
| US20150044288A1 (en) | 2013-07-31 | 2015-02-12 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| WO2016200688A1 (en) | 2015-06-06 | 2016-12-15 | Cloudbreak Therapeutics, Llc | Compositions and methods for treating pterygium |
| KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
| JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
| JP2020512364A (ja) * | 2017-03-28 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 筋ジストロフィーの処置方法において使用するためのニンテダニブ |
| RS67241B1 (sr) | 2017-10-23 | 2025-10-31 | Boehringer Ingelheim Int | Nova kombinacija aktivnih agensa za lečenje progresivnih fibroznih intersticijalnih bolesti pluća (pf-ild) |
| PE20201502A1 (es) | 2018-03-07 | 2020-12-29 | Pliant Therapeutics Inc | Compuestos de aminoacidos y metodos de uso |
| CN115361950A (zh) | 2020-04-01 | 2022-11-18 | 勃林格殷格翰国际有限公司 | 生物标记物在治疗纤维化病症中的用途 |
| EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
| JP2025525881A (ja) | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0169398B1 (de) | 1984-07-24 | 1990-08-29 | R.P. Scherer GmbH | Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung |
| DE19603402A1 (de) | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| SI1948180T1 (sl) * | 2005-11-11 | 2013-06-28 | Boehringer Ingelheim International Gmbh | Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje |
| NO2299987T3 (es) * | 2008-06-06 | 2018-07-21 | ||
| EP2985025B1 (en) * | 2008-06-06 | 2018-01-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination |
| WO2010081817A1 (en) * | 2009-01-14 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
| US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| EP2429520A1 (en) * | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of oncological and fibrotic diseases |
-
2009
- 2009-04-06 UA UAA201100096A patent/UA107560C2/ru unknown
- 2009-06-04 AU AU2009254556A patent/AU2009254556B2/en active Active
- 2009-06-04 EP EP09757601.1A patent/EP2313087B2/en active Active
- 2009-06-04 MX MX2010013092A patent/MX338001B/es active IP Right Grant
- 2009-06-04 TR TR2019/01579T patent/TR201901579T4/tr unknown
- 2009-06-04 CN CN200980121070XA patent/CN102056599A/zh active Pending
- 2009-06-04 WO PCT/EP2009/056895 patent/WO2009147220A1/en not_active Ceased
- 2009-06-04 PT PT09757601T patent/PT2313087T/pt unknown
- 2009-06-04 KR KR1020107027313A patent/KR20110022586A/ko not_active Ceased
- 2009-06-04 BR BRPI0913235A patent/BRPI0913235A2/pt not_active IP Right Cessation
- 2009-06-04 RS RS20190128A patent/RS58280B2/sr unknown
- 2009-06-04 DK DK09757601.1T patent/DK2313087T4/da active
- 2009-06-04 CA CA2726648A patent/CA2726648A1/en not_active Abandoned
- 2009-06-04 PL PL09757601.1T patent/PL2313087T5/pl unknown
- 2009-06-04 ES ES09757601T patent/ES2711913T5/es active Active
- 2009-06-04 PE PE2009000780A patent/PE20100050A1/es not_active Application Discontinuation
- 2009-06-04 LT LTEP09757601.1T patent/LT2313087T/lt unknown
- 2009-06-04 SG SG2013040332A patent/SG191607A1/en unknown
- 2009-06-04 EA EA201001857A patent/EA201001857A1/ru unknown
- 2009-06-04 HU HUE09757601A patent/HUE042524T2/hu unknown
- 2009-06-04 SI SI200931930T patent/SI2313087T2/sl unknown
- 2009-06-04 FI FIEP09757601.1T patent/FI2313087T4/fi active
- 2009-06-04 HR HRP20190181TT patent/HRP20190181T4/hr unknown
- 2009-06-04 JP JP2011512134A patent/JP5583119B2/ja active Active
- 2009-06-04 US US12/995,893 patent/US20110190318A1/en not_active Abandoned
- 2009-06-05 TW TW098118827A patent/TW201002692A/zh unknown
- 2009-06-05 AR ARP090102040A patent/AR072060A1/es unknown
- 2009-06-08 UY UY0001031876A patent/UY31876A/es not_active Application Discontinuation
-
2010
- 2010-11-01 IL IL209055A patent/IL209055A0/en unknown
- 2010-11-08 ZA ZA2010/07972A patent/ZA201007972B/en unknown
- 2010-12-03 CO CO10152530A patent/CO6280468A2/es not_active Application Discontinuation
- 2010-12-06 CL CL2010001362A patent/CL2010001362A1/es unknown
- 2010-12-06 MA MA33403A patent/MA32386B1/fr unknown
- 2010-12-23 EC EC2010010717A patent/ECSP10010717A/es unknown
-
2013
- 2013-03-08 US US13/790,334 patent/US20130203773A1/en not_active Abandoned
-
2014
- 2014-02-10 US US14/176,478 patent/US20140163040A1/en not_active Abandoned
- 2014-02-28 JP JP2014039871A patent/JP5992937B2/ja active Active
-
2019
- 2019-02-19 CY CY20191100212T patent/CY1121272T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20100050A1 (es) | Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona | |
| UY31879A (es) | Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspensión de un derivado de indolinona | |
| CY1121107T1 (el) | Φαρμακοτεχνικες μορφες δισκιων αμεσης απελευθερωσης | |
| UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
| EA201071288A1 (ru) | Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина | |
| EA201290394A1 (ru) | Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7 | |
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| CY1115994T1 (el) | Φαρμακευτικες τυποποιησεις οι οποιες περιεχουν προσδεματα υποδοχεα ντοπαμινης | |
| MY149731A (en) | Compounds | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| PE20140604A1 (es) | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| EA201691322A1 (ru) | Фармацевтическая композиция ингибитора dpp-iv в комбинации с метформином | |
| EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| EA201270428A1 (ru) | Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины | |
| TNSN07337A1 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| MX378947B (es) | Composición farmacéutica estable para administración oral. | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| EA201691034A1 (ru) | Композиции в твердой форме с замедленным высвобождением для перорального введения | |
| ATE522515T1 (de) | Modulatoren der dopamin-neurotransmission | |
| EA201170843A1 (ru) | Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью | |
| EA201891027A1 (ru) | Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение | |
| EA201490342A1 (ru) | Производные пиразолина и их применение в качестве селективных модуляторов рецептора андрогена | |
| TN2010000555A1 (en) | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |